KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Non-Current Assets (2016 - 2025)

Travere Therapeutics' Other Non-Current Assets history spans 13 years, with the latest figure at $8.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 51.11% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $8.9 million, down 51.11%, while the annual FY2025 figure was $8.9 million, 51.11% down from the prior year.
  • Other Non-Current Assets reached $8.9 million in Q4 2025 per TVTX's latest filing, down from $10.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $35.0 million in Q1 2021 to a low of $8.9 million in Q4 2025.
  • Average Other Non-Current Assets over 5 years is $16.9 million, with a median of $11.8 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: surged 414.92% in 2021, then plummeted 69.08% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $11.1 million in 2021, then dropped by 3.48% to $10.7 million in 2022, then decreased by 0.22% to $10.7 million in 2023, then surged by 70.36% to $18.2 million in 2024, then tumbled by 51.11% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Other Non-Current Assets are $8.9 million (Q4 2025), $10.3 million (Q3 2025), and $19.6 million (Q2 2025).